checkAd
    Startseite > Aktien > Intec Pharma > Nachrichten
    Intec Pharma Aktie
    8,9400
     
    USD
    +247,90 %
    +6,3703 USD
    Letzter Kurs 28.07.21 NYSE
    8,9600
     
    USD
    100 STK
    Geldkurs 28.07.21
    9,1500
     
    USD
    400 STK
    Briefkurs 28.07.21
    ISIN: IL0011177958 · WKN: A1C7WG · Israel

    Neueste Nachrichten

    Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
    11.04.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
    28.03.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
    25.03.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
    18.03.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
    13.03.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
    04.03.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
    15.02.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
    08.02.24 · globenewswire · Intec Pharma
    European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
    04.01.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    06.11.23 · globenewswire · Intec Pharma
    Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
    06.11.23 · globenewswire · Intec Pharma
    Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
    31.10.23 · globenewswire · Intec Pharma